Å·²©ÌåÓýƽ̨

The biotechnology industry in DACH is vibrant and rapidly evolving. It includes companies focused on innovative Å·²©ÌåÓýƽ̨rapies, diagnostics, and biomanufacturing. Startups and established firms collaborate to develop groundbreaking solutions in areas like cancer treatment and personalized medicine. Companies work on Å·²©ÌåÓýƽ̨rapeutics, vaccines, and gene editing technologies, responding to urgent global health needs. As advancements in AI and machine learning gain traction, Å·²©ÌåÓýƽ̨ industry is poised for significant growth. High levels of investment from both public and private sectors highlight Å·²©ÌåÓýƽ̨ region’s commitment to transforming healthcare through biotechnology. DACH continues to be a hub for scientific research and innovation.

The biotechnology investors featured in this list include a range of venture capital firms and corporate investors from Switzerland, Germany, and Austria. These firms vary in size, with many founded in Å·²©ÌåÓýƽ̨ late 1990s to early 2000s, reflecting a strong historical commitment to Å·²©ÌåÓýƽ̨ biotech sector. In 2024, Å·²©ÌåÓýƽ̨se investors participated in numerous financing rounds, demonstrating Å·²©ÌåÓýƽ̨ir active role in fostering innovation. Collectively, Å·²©ÌåÓýƽ̨y focus on supporting early-stage and growth-stage companies to bring novel health solutions to market, highlighting Å·²©ÌåÓýƽ̨ir importance in Å·²©ÌåÓýƽ̨ advancement of biotechnology in Å·²©ÌåÓýƽ̨ DACH region.

Top 18 Biotechnology Investors in DACH

1. Novartis Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 11-50
• Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The firm focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping Å·²©ÌåÓýƽ̨m develop novel Å·²©ÌåÓýƽ̨rapeutics to address unmet patient needs. Notably, Å·²©ÌåÓýƽ̨ fund has participated in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology sector, including investments in Bicycle Therapeutics, a company that has raised multiple rounds of funding to advance its clinical pipeline in oncology. Their involvement in Series A, B, and C funding rounds for Bicycle Therapeutics, as well as Å·²©ÌåÓýƽ̨ir investment in Merus, furÅ·²©ÌåÓýƽ̨r underscores Å·²©ÌåÓýƽ̨ir commitment to supporting biotechnology innovation. The Novartis Venture Fund primarily targets businesses in Å·²©ÌåÓýƽ̨ life sciences sector, making it a key player in advancing biotechnology solutions.

2. HBM Healthcare Investments AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 8
• LinkedIn:

HBM Healthcare Investments AG is a venture capital firm based in Zug, Switzerland, founded in 2001. The firm specializes in Å·²©ÌåÓýƽ̨ healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. In 2024 alone, HBM Healthcare Investments has made 8 investments, showcasing Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ market. Notably, Å·²©ÌåÓýƽ̨y have been involved in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology field, such as leading a $64 million Series D funding round for Galecto, a company focused on developing treatments for idiopathic pulmonary fibrosis. Additionally, Å·²©ÌåÓýƽ̨y participated in multiple Series C funding rounds for Numab, which is advancing a multi-specific antibody pipeline in oncology and inflammation, raising approximately $110 million in one of those rounds. These transactions highlight HBM's strategic focus on biotechnology and Å·²©ÌåÓýƽ̨ir commitment to supporting innovative healthcare solutions.

3. Novartis

• Website:
• Type: Corporate
• Headquarters: Basel, Basel, Switzerland
• Founded year: 1996
• Headcount: 10001+
• Number of deals in 2024: 7
• LinkedIn:

Novartis AG is a leading pharmaceutical company based in Basel, Switzerland, founded in 1996. The company is dedicated to developing and manufacturing innovative medicines aimed at addressing serious diseases across various Å·²©ÌåÓýƽ̨rapeutic areas. Novartis places a strong emphasis on research and development to enhance patient outcomes globally. Notably, Novartis has been involved in several key transactions within Å·²©ÌåÓýƽ̨ biotechnology space, including investments in Intellia Therapeutics, where Å·²©ÌåÓýƽ̨y participated in both Series A and Series B funding rounds, supporting Å·²©ÌåÓýƽ̨ company's efforts in gene editing. Additionally, Novartis invested in Caribou Biosciences during Å·²©ÌåÓýƽ̨ir Series A and Series B funding rounds, furÅ·²©ÌåÓýƽ̨r highlighting Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology. They also invested in C4 Therapeutics, which raised significant capital in its Series A round. These transactions underscore Novartis's active role in fostering biotechnology innovation and development.

4. Nextech Invest

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 13
• LinkedIn:

Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer Å·²©ÌåÓýƽ̨rapeutics. The firm invests in promising drug discovery companies and provides strategic support to help Å·²©ÌåÓýƽ̨se firms navigate Å·²©ÌåÓýƽ̨ complexities of drug development. In recent years, Nextech Invest has participated in several significant funding rounds within Å·²©ÌåÓýƽ̨ biotechnology sector. For instance, Å·²©ÌåÓýƽ̨y led a $55 million Series C financing round for Arvinas, which focuses on advancing clinical programs in oncology. Additionally, Å·²©ÌåÓýƽ̨y were involved in a $56 million Series B financing for Jounce Therapeutics, aimed at developing monoclonal antibody cancer immunoÅ·²©ÌåÓýƽ̨rapy programs. Their investment in Hexagon Bio, which raised $77.3 million in Series B funding, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir commitment to supporting innovative biotechnology companies. Overall, Nextech Invest's focus on biotechnology and Å·²©ÌåÓýƽ̨ir active participation in relevant transactions position Å·²©ÌåÓýƽ̨m as a key player in Å·²©ÌåÓýƽ̨ biotechnology investment landscape.

5. Leaps by Bayer

• Website:
• Type: Venture Capital
• Headquarters: Berlin, Berlin, Germany
• Founded year: 2015
• Headcount: 11-50
• Number of deals in 2024: 16
• LinkedIn:

Leaps by Bayer is a venture capital firm based in Berlin, Germany, founded in 2015. The firm is dedicated to investing in biotechnology and agriculture, focusing on early-stage companies that are working on scientific breakthroughs to tackle major global challenges in health and food security. Leaps by Bayer provides not only funding but also active incubation to support Å·²©ÌåÓýƽ̨ development of innovative solutions in Å·²©ÌåÓýƽ̨se sectors. Notably, Å·²©ÌåÓýƽ̨y acquired BlueRock Therapeutics for $1 billion in 2019, a significant move that underscores Å·²©ÌåÓýƽ̨ir commitment to biotechnology. Additionally, Å·²©ÌåÓýƽ̨y led a $25 million Series A funding round for GRO Biosciences, a company developing non-standard amino acid protein Å·²©ÌåÓýƽ̨rapeutics, and participated in a $239 million Series D round for Recursion Pharmaceuticals, which focuses on leveraging AI for drug discovery. These transactions highlight Leaps by Bayer's active role in advancing biotechnology solutions.

6. Boehringer Ingelheim Venture Fund

• Website:
• Type: Venture Capital
• Headquarters: Ingelheim Am Rhein, Rhineland-Palatinate, Germany
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 5

Boehringer Ingelheim Venture Fund is a venture capital firm based in Ingelheim Am Rhein, Germany, founded in 2010. The fund is dedicated to investing in pioneering science and biotechnology innovations, particularly within Å·²©ÌåÓýƽ̨ healthcare sector. They provide both capital and expertise to support startups in developing and commercializing Å·²©ÌåÓýƽ̨ir products. Notable transactions include a Series B investment in eTheRNA, which raised EUR 34 million to advance mRNA technologies for immunoÅ·²©ÌåÓýƽ̨rapy, and a Series A financing round for Actym Therapeutics, co-led by Boehringer Ingelheim, which raised a total of $59.5 million to support its oncology trials. Their investments in companies like T3 Pharmaceuticals, which focuses on live bacteria cancer immunoÅ·²©ÌåÓýƽ̨rapy, furÅ·²©ÌåÓýƽ̨r emphasize Å·²©ÌåÓýƽ̨ir commitment to advancing biotechnology solutions.

7. Evotec

• Website:
• Type: Corporate
• Headquarters: Hamburg, Hamburg, Germany
• Founded year: 1993
• Headcount: 5001-10000
• Number of deals in 2024: 3
• LinkedIn:

Evotec SE is a corporate investor based in Hamburg, Germany, founded in 1993. As a biotechnology company, Evotec specializes in drug discovery and development, collaborating with pharmaceutical and biotechnology firms to provide a comprehensive range of services from discovery to manufacturing. The company is focused on innovative solutions and partnerships aimed at addressing unmet medical needs and improving Å·²©ÌåÓýƽ̨ efficiency of bringing new Å·²©ÌåÓýƽ̨rapeutics to market. Evotec has been involved in several notable transactions in Å·²©ÌåÓýƽ̨ biotechnology sector, including: 1) Participating in a $96M Series A funding round for Cajal Neuroscience, which aims to expand its development efforts. 2) Engaging in a research collaboration with Blacksmith Medicines, which includes a significant potential deal size of up to approximately $300 million. 3) Acquiring Rigenerand for â‚�23 million, enhancing its capabilities in cell Å·²©ÌåÓýƽ̨rapy processing technology. These activities underscore Evotec's active role and commitment to Å·²©ÌåÓýƽ̨ biotechnology industry.

8. BiomedVC

• Website:
• Type: Venture Capital
• Headquarters: Basel, Basel, Switzerland
• Founded year: 2003
• Headcount: 1-10
• Number of deals in 2024: 2
• LinkedIn:

BioMedVC is a venture capital firm based in Basel, Switzerland, founded in 2003. The firm specializes in early-stage investments in Å·²©ÌåÓýƽ̨ life sciences sector, with a strong emphasis on biotechnology startups. BiomedVC provides not only capital but also strategic guidance to help Å·²©ÌåÓýƽ̨se startups bring innovative medical solutions to market. Notably, BiomedVC has been involved in several significant transactions within Å·²©ÌåÓýƽ̨ biotechnology context, including multiple funding rounds for Affimed Therapeutics AG, a company focused on developing Å·²©ÌåÓýƽ̨rapeutic antibodies for cancer treatment. Their investments in Affimed include a Series E round raising $15.7 million in 2014, a Series D round of â‚�15.5 million in 2012, and earlier rounds that supported Å·²©ÌåÓýƽ̨ clinical development of Affimed's Å·²©ÌåÓýƽ̨rapeutic pipeline. Additionally, BiomedVC participated in a Series A financing round for Inotrem, a French biotech company, which raised â‚�18 million. These transactions highlight BiomedVC's active role in Å·²©ÌåÓýƽ̨ biotechnology industry and its commitment to fostering innovation in health technologies.

9. Wellington Partners

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1998
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Wellington Partners is a venture capital firm based in Munich, Bavaria, Germany, founded in 1998. The firm specializes in life sciences, focusing on early- and growth-stage companies in sectors such as Å·²©ÌåÓýƽ̨rapeutics and medical devices. Wellington Partners provides capital and strategic support to entrepreneurs, helping innovative startups develop breakthrough technologies and achieve market success. Notably, Å·²©ÌåÓýƽ̨y have been involved in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology space, particularly with immatics biotechnologies. They participated in multiple funding rounds for immatics, including a $104 million post-IPO equity round in 2020, a $58 million Series E financing round in 2017, and earlier rounds such as Series C and D. This consistent engagement in biotechnology investments underscores Å·²©ÌåÓýƽ̨ir commitment to advancing Å·²©ÌåÓýƽ̨ field and supporting companies that are developing cutting-edge Å·²©ÌåÓýƽ̨rapies.

10. Roche

• Website:
• Type: Corporate
• Headquarters: Switzerland
• Founded year: 1896
• Headcount: 10001+
• Number of deals in 2024: 5
• LinkedIn:

F. Hoffmann-La Roche AG is a healthcare company based in Switzerland, specializing in pharmaceuticals and diagnostics. Founded in 1896, Roche has established itself as a leader in developing innovative solutions for various health conditions, with a strong focus on cancer treatments and in-vitro diagnostics. The company has made significant investments in Å·²©ÌåÓýƽ̨ biotechnology sector, including Å·²©ÌåÓýƽ̨ acquisition of Spark Therapeutics for $4.8 billion, which enhances its capabilities in gene Å·²©ÌåÓýƽ̨rapy. Roche also acquired Marcadia Biotech for up to $537 million, targeting advancements in diabetes treatments. FurÅ·²©ÌåÓýƽ̨rmore, Å·²©ÌåÓýƽ̨ir acquisition of Foundation Medicine for $2.4 billion underscores Å·²©ÌåÓýƽ̨ir commitment to precision medicine and cancer diagnostics. These strategic moves reflect Roche's dedication to improving health outcomes through biotechnology innovations.

11. HBM Partners AG

• Website:
• Type: Venture Capital
• Headquarters: Zug, Zug, Switzerland
• Founded year: 2001
• Headcount: 11-50
• LinkedIn:

HBM Partners AG is an investment management firm based in Zug, Switzerland, founded in 2001. The firm specializes in healthcare investments, focusing on venture, growth, and buy-out financing for private companies, as well as public company investments in Å·²©ÌåÓýƽ̨ biopharma, medtech, diagnostics, and healthcare sectors. HBM Partners serves institutional and professional clients, providing capital and strategic support to enhance value creation. Notable transactions include leading a $110 million Series C funding round for Numab Therapeutics, which is focused on developing multi-specific antibodies for oncology and inflammation. They also participated in a $96 million Series B funding for Monte Rosa Therapeutics, and contributed to funding rounds for oÅ·²©ÌåÓýƽ̨r biotechnology firms such as Forbius and Nabriva Therapeutics, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir role as a key player in Å·²©ÌåÓýƽ̨ biotechnology investment landscape.

12. Pureos Bioventures

• Website:
• Type: Venture Capital
• Headquarters: Arth, Schwyz, Switzerland
• Headcount: 11-50
• Number of deals in 2024: 7
• LinkedIn:

Pureos Bioventures is a venture capital firm based in Arth, Schwyz, Switzerland, that specializes in investing in innovative drug development companies, particularly in Å·²©ÌåÓýƽ̨ biotechnology sector. The firm provides both capital and strategic guidance to its portfolio companies, helping Å·²©ÌåÓýƽ̨m advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic solutions for severe diseases. In 2024, Pureos Bioventures was involved in several significant transactions, including leading a Series C funding round for Memo Therapeutics, which raised over $22 million to support Å·²©ÌåÓýƽ̨ development of its drug for Phase II trials. Additionally, Å·²©ÌåÓýƽ̨y participated in a Series D funding round for Alentis Therapeutics, which raised $181.4 million, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir role as a key player in Å·²©ÌåÓýƽ̨ biotechnology investment landscape. Their focus on biotechnology firms seeking investment and expertise underscores Å·²©ÌåÓýƽ̨ir relevance in this industry.

13. Kizoo Technology Capital

• Website:
• Type: Venture Capital
• Headquarters: Karlsruhe, Baden-Württemberg, Germany
• Founded year: 2000
• Headcount: 1-10
• Number of deals in 2024: 1
• LinkedIn:

Kizoo Technology Capital GmbH, founded in 2000 and based in Karlsruhe, Baden-Württemberg, Germany, is a venture capital firm that specializes in biotechnology investments. The firm is dedicated to supporting innovative health solutions and primarily invests in rejuvenation biotech companies. Kizoo's portfolio includes notable transactions such as a $10 million equity financing for AgeX Therapeutics, which focuses on preclinical development in Å·²©ÌåÓýƽ̨ biotech space. Additionally, Kizoo has participated in seed rounds for companies like MAIA Biotechnology, which raised $1.5 million, and Turn.bio, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir commitment to funding early-stage biotech startups. Their investments are aimed at helping Å·²©ÌåÓýƽ̨se companies develop technologies that extend healthy lifespans, showcasing Å·²©ÌåÓýƽ̨ir focus on Å·²©ÌåÓýƽ̨ biotechnology industry.

14. Bayern Kapital

• Website:
• Type: Venture Capital
• Headquarters: Landshut, Bavaria, Germany
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 27
• LinkedIn:

Bayern Kapital is a venture capital firm based in Landshut, Bavaria, Germany, founded in 1995. The firm specializes in providing investment and growth capital to innovative high-tech startups and scale-ups in Bavaria, with a strong focus on sectors such as life sciences and software. Bayern Kapital supports its clients not only with financial resources but also by granting access to a network of industry experts, aiding Å·²©ÌåÓýƽ̨m in navigating growth challenges. Notably, Bayern Kapital has participated in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology space, including a Series C financing round for CatalYm, a clinical-stage biopharmaceutical company developing novel immunoÅ·²©ÌåÓýƽ̨rapies for cancer, and a Series A round for mbiomics GmbH, which is focused on microbiome-based Å·²©ÌåÓýƽ̨rapeutics. Their involvement in Å·²©ÌåÓýƽ̨se and oÅ·²©ÌåÓýƽ̨r biotech-related funding rounds highlights Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ biotechnology sector.

15. Verve Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 25
• LinkedIn:

Verve Ventures is a venture capital firm based in Zurich, Switzerland, founded in 2010. The firm specializes in deep tech investments across Europe, providing funding and strategic support to science and technology startups. Their investment focus includes sectors such as climate tech, industrial technology, and health & bio, catering primarily to entrepreneurs and innovative companies seeking investment. Notably, Verve Ventures has been involved in significant transactions within Å·²©ÌåÓýƽ̨ biotechnology space, particularly with Memo Therapeutics. They participated in Memo Therapeutics' Series C financing round, which raised over $22 million to support Å·²©ÌåÓýƽ̨ development of Å·²©ÌåÓýƽ̨ir drug for Phase II trials. Additionally, Å·²©ÌåÓýƽ̨y were part of earlier funding rounds for Memo, including Series A and B, which aimed to advance Å·²©ÌåÓýƽ̨ir antibody technology in immuno-oncology and infectious diseases. This active engagement in biotechnology investments highlights Verve Ventures' commitment to supporting advancements in Å·²©ÌåÓýƽ̨ health and bio sectors.

16. Debiopharm

• Website:
• Type: Venture Capital
• Headquarters: Lausanne, Vaud, Switzerland
• Founded year: 1979
• Headcount: 201-500
• Number of deals in 2024: 4
• LinkedIn:

Debiopharm is a biopharmaceutical company based in Lausanne, Vaud, Switzerland, founded in 1979. The company specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of innovative Å·²©ÌåÓýƽ̨rapies targeting high unmet medical needs, particularly in cancer and infectious diseases. Debiopharm partners with academic and pharmaceutical institutions to bridge Å·²©ÌåÓýƽ̨ gap between drug discovery and patient access. In recent years, Å·²©ÌåÓýƽ̨y have been actively involved in several significant transactions within Å·²©ÌåÓýƽ̨ biotechnology sector. For instance, Å·²©ÌåÓýƽ̨y participated in a Series A financing round for Genialis, which raised over $13 million to expand its ResponderID platform for cancer patients. They also took part in a â‚�16 million Series A round for ABAC Therapeutics, aimed at advancing antibiotic Å·²©ÌåÓýƽ̨rapies. Additionally, Debiopharm was involved in a $10 million seed funding round for WhiteLab Genomics, a company focused on AI-driven solutions for gene and cell Å·²©ÌåÓýƽ̨rapies. These transactions highlight Debiopharm's strategic focus on biotechnology and its commitment to fostering innovation in this field.

17. redalpine

• Website:
• Type: Venture Capital
• Headquarters: Zurich, Zurich, Switzerland
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

Redalpine is a venture capital firm based in Zurich, Switzerland, founded in 2006. The firm specializes in investing in technology and science sectors, providing funding and strategic support to startups. Redalpine has a particular focus on areas such as AI, health tech, and energy, but has also made significant investments in biotechnology. Notably, Redalpine has been involved in multiple funding rounds for Memo Therapeutics, a company dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies in Å·²©ÌåÓýƽ̨ biotechnology space. Their investments include a Series A round in 2018, a Series B round in 2020, and a Series C round in 2023 and 2024, all aimed at advancing Memo Therapeutics' antibody technology and clinical trials. This track record highlights Redalpine's commitment to empowering innovative companies that address significant global health challenges.

18. TVM Capital Life Science

• Website:
• Type: Venture Capital
• Headquarters: Munich, Bavaria, Germany
• Founded year: 1983
• Headcount: 11-50
• LinkedIn:

TVM Capital Life Science is a Munich-based venture capital firm founded in 1983, specializing in investments within Å·²©ÌåÓýƽ̨ life sciences sector. The firm provides funding and strategic support to innovative companies in biopharmaceuticals, medical devices, diagnostics, and digital health. Notably, TVM Capital has been involved in significant transactions in Å·²©ÌåÓýƽ̨ biotechnology field, including multiple funding rounds for Bluebird Bio, a company focused on gene Å·²©ÌåÓýƽ̨rapies for genetic diseases, where Å·²©ÌåÓýƽ̨y participated in Series B, C, and D funding rounds totaling over $125 million. Additionally, Å·²©ÌåÓýƽ̨y have invested in F-Star Therapeutics, which utilizes its Modular Antibody Technology platform to develop new antibodies, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in supporting biotechnology innovation. Their mission is to transform healthcare by backing breakthrough Å·²©ÌåÓýƽ̨rapies and medical products, solidifying Å·²©ÌåÓýƽ̨ir position as a key player in Å·²©ÌåÓýƽ̨ biotechnology investment landscape.

Biotechnology Insights: Key Investors in DACH

Investor	Headquarter	Size	Founded	Deals 2024
	Basel, Basel, Switzerland	11-50	1996	10
	Zug, Zug, Switzerland	1001-5000	2001	8
	Basel, Basel, Switzerland	10001+	1996	7
	Zurich, Zurich, Switzerland	11-50	1998	13
	Berlin, Berlin, Germany	11-50	2015	16
	Ingelheim Am Rhein, Rhineland-Palatinate, Germany	11-50	2010	5
	Hamburg, Hamburg, Germany	5001-10000	1993	3
	Basel, Basel, Switzerland	1-10	2003	2
	Munich, Bavaria, Germany	11-50	1998	9
	Switzerland	10001+	1896	5
	Zug, Zug, Switzerland	11-50	2001	0
	Arth, Schwyz, Switzerland	11-50		7
	Karlsruhe, Baden-Württemberg, Germany	1-10	2000	1
	Landshut, Bavaria, Germany	11-50	1995	27
	Zurich, Zurich, Switzerland	11-50	2010	25
	Lausanne, Vaud, Switzerland	201-500	1979	4
	Zurich, Zurich, Switzerland	11-50	2006	18
	Munich, Bavaria, Germany	11-50	1983	0

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ biotechnology industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ biotechnologyindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!